Home Cart Sign in  
Chemical Structure| 1564286-55-0 Chemical Structure| 1564286-55-0

Structure of CWHM-12
CAS No.: 1564286-55-0

Chemical Structure| 1564286-55-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

CWHM-12 is an effective inhibitor of αV integrin, with IC50 values of 0.2, 0.8, 1.5, and 1.8 nM for αvβ8, αvβ3, αvβ6, and αvβ1, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of CWHM-12

CAS No. :1564286-55-0
Formula : C26H32BrN5O6
M.W : 590.47
SMILES Code : O=C(O)C[C@@H](C1=CC(C(C)(C)C)=CC(Br)=C1)NC(CNC(C2=CC(NC3=NCC(O)CN3)=CC(O)=C2)=O)=O
MDL No. :MFCD28385850

Safety of CWHM-12

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of CWHM-12

cytoskeleton

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 female mice Cerulein-induced chronic pancreatitis model Subcutaneous continuous infusion 100 mg/kg Starting 3 days before cerulein administration and continued until the end of the experiment To evaluate the preventive effect of CWHM-12 on pancreatic fibrosis, results showed CWHM-12 significantly reduced fibrosis, PSC activation, and expression of TGFB-regulated genes Cell Mol Gastroenterol Hepatol. 2016 Mar 16;2(4):499-518
Mice Choline deficient, amino-acid defined, high-fat diet (CDAHFD) mouse model Subcutaneous continuous infusion 100 mg/kg Continuous for 4 weeks To evaluate the efficacy of CWHM-12 in reversing liver fibrosis in a mouse model of nonalcoholic steatohepatitis (NASH). Results showed that CWHM-12 significantly reduced liver fibrosis, decreased activation and number of hepatic stellate cells, and reduced TGF-β signaling. Hepatol Commun. 2018 Dec 27;3(2):246-261
C3HeB/FeJ mice Mycobacterium tuberculosis infection model Subcutaneous osmotic pump 100 mg/kg Continuous administration until 42 dpi To evaluate the protective effect of CWHM-12 during early Mycobacterium tuberculosis infection, results showed that CWHM-12 treatment reduced bacterial burden in the lung and spleen, decreased production of iNOS, MIP-2, and IL-10, and increased collagen deposition J Interferon Cytokine Res. 2022 Aug;42(8):421-429

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.69mL

0.34mL

0.17mL

8.47mL

1.69mL

0.85mL

16.94mL

3.39mL

1.69mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories